Abstract
Purpose Motion-impaired CT images can result in limited or suboptimal diagnostic interpretation (with missed or miscalled lesions) and patient recall. We trained and tested an artificial intelligence (AI) model for identifying substantial motion artifacts on CT pulmonary angiography (CTPA) that have a negative impact on diagnostic interpretation.
Methods With IRB approval and HIPAA compliance, we queried our multicenter radiology report database (mPower, Nuance) for CTPA reports between July 2015 - March 2022 for the following terms: “motion artifacts,” “respiratory motion,” “technically inadequate,” and “suboptimal” or “limited exam.” All CTPA reports belonged to two quaternary (Site A, n= 335; B, n= 259) and a community (C, n= 199) healthcare sites. A thoracic radiologist reviewed CT images of all positive hits for motion artifacts (present or absent) and their severity (no diagnostic effect or major diagnostic impairment). Coronal multiplanar images belonging to 793 CTPA exams were de-identified and exported offline into an AI model building prototype (Cognex Vision Pro, Cognex Corporation) to train an AI model to perform two-class classification (“motion” or “no motion”) with data from the three sites (70% training dataset, n= 554; 30% validation dataset, n= 239). Separately, data from Site A and Site C were used for training and validating; testing was performed on the Site B CTPA exams. A 5-fold repeated cross-validation was performed to evaluate the model performance with accuracy and receiver operating characteristics analysis (ROC).
Results Among the CTPA images from 793 patients (mean age 63 ± 17 years; 391 males, 402 females), 372 had no motion artifacts, and 421 had substantial motion artifacts. The statistics for the average performance of the AI model after 5-fold repeated cross-validation for the two-class classification included 94% sensitivity, 91% specificity, 93% accuracy, and 0.93 area under the ROC curve (AUC: 95% CI 0.89-0.97).
Conclusion The AI model used in this study can successfully identify CTPA exams with diagnostic interpretation limiting motion artifacts in multicenter training and test datasets.
Clinical relevance The AI model used in the study can help alert the technologists about the presence of substantial motion artifacts on CTPA where a repeat image acquisition can help salvage diagnostic information.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: MKK received unrelated research grants from Siemens Healthineers, Riverain Tech., and Coreline Inc. SRD has received unrelated grants/ research supports from Vuno, Lunit, GE, Qure AI Royalties from Elsievier Receipt of honoraria or consultation fees from SIEMENS Healthineers and has participated in a company sponsored speaker?s bureau by Siemens Healthineers and provides independent image analysis for hospital-contracted clinical research trials programs for Merck, Pfizer, Bristol Myers Squibb, Novartis, Roche, Polaris, Cascadian, Abbvie, Gradalis, Bayer, Zai laboratories, Biengen, Shanghai Biosciences, Resonance, Analise. The Data Science Office (DSO) at Mass General Brigham is funded in part by monies and resources from Cognex Corporation. JH has participated in artificial intelligence model development and validation, which receive funding through collaborations with industry partners through his work for the Data Science Office at Mass General Brigham. He is listed as an inventor on a patent for a CTA Large Vessel Occlusion model. He also reports stock or stock options as an investor in Elly Health. Other co-authors have no competing interests.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mass General Brigham IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
